Skip to main content
. 2018 Oct;28(10):1494–1507. doi: 10.1101/gr.237180.118

Figure 5.

Figure 5.

The PRC1-dependent nucleosome landscape is linked to, but not explained by, RNA polymerase II activity. (A) A schematic depicting the inhibition of RNA polymerase II (RNA POLII) occupancy using triptolide (TRP). (B) A box plot comparing the median Tn5-tagmented fragment sizes for PcG and non-PcG CGI promoters before and after TRP treatment. (C) A box plot quantifying the NucleoATAC-derived nucleosome occupancy score for PcG and non-PcG CGI promoters before and after TRP treatment. (D) A box plot comparing the median inter-dyad distances for PcG and non-PcG CGI promoters before and after TRP treatment. (E) A Venn diagram for PcG-occupied CGI promoters with significant increases in gene expression in Ring1−/−;Rnf2fl/fl and Ring1−/−;Rnf2fl/fl;Eed−/− ATAC-seq before and after tamoxifen (TAM), corresponding to PRC1-null, PRC2-null, and PRC1/2-null (FDR < 0.05; fold change > 2). (F) A bar plot depicting the number of significant RNA-seq expression changes for PcG-occupied CGI promoters. (G) Same as in F, only for ATAC-seq. Changes in ATAC-seq were calculated using the CGI promoter interval. (H) A box plot comparing the change in RNA-seq log2 fold change (log2FC) for PcG-occupied CGI promoters with (up-regulated) or without (no change) an increase in gene expression for each cell line and treatment. (I) A box plot comparing the change in median Tn5-tagmented fragment sizes for PcG-occupied CGI promoters with (up-regulated) or without (no change) an increase in gene expression for each cell line and treatment. (J) A box plot quantifying the log2 fold change (log2FC) in NucleoATAC-derived nucleosome occupancy for PcG-occupied CGI promoters with (up-regulated) or without (no change) an increase in gene expression for each cell line and treatment. (K) A box plot comparing the difference in median inter-dyad distances for PcG-occupied CGI promoters with (up-regulated) or without (no change) an increase in gene expression for each cell line and treatment.